{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:55:47Z","timestamp":1793105747857,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40265-024-02095-4","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T04:11:42Z","timestamp":1728015102000},"page":"1379-1394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Emerging Biologic Therapies for the Treatment of Atopic Dermatitis"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2552-9333","authenticated-orcid":false,"given":"Jos\u00e9 Miguel","family":"Alvarenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-3817","authenticated-orcid":false,"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"2095_CR1","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Z\u00e4ch S, Taieb A, Paul C, Thyssen JP, De Bruin-Weller M, et al. ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Acad Dermatol Venereol. 2020;34:2717\u201344.","journal-title":"Acad Dermatol Venereol"},{"key":"2095_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1.","journal-title":"Nat Rev Dis Primers"},{"key":"2095_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/all.16009","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Maintz L, Bieber T. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. Allergy. 2024. https:\/\/doi.org\/10.1111\/all.16009.","journal-title":"Allergy"},{"key":"2095_CR4","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1007\/s12325-022-02197-z","volume":"39","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Lafeuille M-H, Emond B, Fakih I, Duh MS, Cappelleri JC, et al. Real-world effectiveness of newly initiated systemic therapy for atopic dermatitis in the united states: a claims database analysis. Adv Ther. 2022;39:4157\u201368.","journal-title":"Adv Ther"},{"key":"2095_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40:84\u201392.","journal-title":"Allergy Asthma Proc"},{"key":"2095_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.anai.2019.10.008","volume":"124","author":"C Drislane","year":"2020","unstructured":"Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020;124:36\u201343.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2095_CR7","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.3390\/cells10092386","volume":"10","author":"M Fujii","year":"2021","unstructured":"Fujii M. The pathogenic and therapeutic implications of ceramide abnormalities in atopic dermatitis. Cells. 2021;10:2386.","journal-title":"Cells"},{"key":"2095_CR8","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/eji.200425196","volume":"34","author":"J Strid","year":"2004","unstructured":"Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol. 2004;34:2100\u20139.","journal-title":"Eur J Immunol"},{"key":"2095_CR9","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000110","author":"EB Brandt","year":"2011","unstructured":"Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011. https:\/\/doi.org\/10.4172\/2155-9899.1000110.","journal-title":"J Clin Cell Immunol."},{"key":"2095_CR10","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.3390\/ijms221910661","volume":"22","author":"P Gallegos-Alcal\u00e1","year":"2021","unstructured":"Gallegos-Alcal\u00e1 P, Jim\u00e9nez M, Cervantes-Garc\u00eda D, Salinas E. The keratinocyte as a crucial cell in the predisposition, onset, progression, therapy and study of the atopic dermatitis. IJMS. 2021;22:10661.","journal-title":"IJMS."},{"key":"2095_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1146\/annurev.immunol.17.1.701","volume":"17","author":"K Nelms","year":"1999","unstructured":"Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. THE IL-4 RECEPTOR: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701\u201338.","journal-title":"Annu Rev Immunol"},{"key":"2095_CR12","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","volume":"9","author":"IS Junttila","year":"2018","unstructured":"Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888.","journal-title":"Front Immunol"},{"key":"2095_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13601-020-00338-7","volume":"10","author":"FMS Badloe","year":"2020","unstructured":"Badloe FMS, De Vriese S, Coolens K, Schmidt-Weber CB, Ring J, Gutermuth J, et al. IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis. Clin Transl Allergy. 2020;10:34.","journal-title":"Clin Transl Allergy."},{"key":"2095_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/09546634.2017.1290205","volume":"28","author":"MD Saleem","year":"2017","unstructured":"Saleem MD, Oussedik E, D\u2019Amber V, Feldman SR. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatol Treat. 2017;28:591\u20139.","journal-title":"J Dermatol Treat"},{"key":"2095_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2013.04.028","volume":"72","author":"H Fujita","year":"2013","unstructured":"Fujita H. The role of IL-22 and Th22 cells in human skin diseases. J Dermatol Sci. 2013;72:3\u20138.","journal-title":"J Dermatol Sci"},{"key":"2095_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","volume":"20","author":"P Facheris","year":"2023","unstructured":"Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20:448\u201374.","journal-title":"Cell Mol Immunol"},{"key":"2095_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.911546","volume":"13","author":"Y Pan","year":"2022","unstructured":"Pan Y, Du D, Wang L, Wang X, He G, Jiang X. The role of T helper 22 cells in dermatological disorders. Front Immunol. 2022;13: 911546.","journal-title":"Front Immunol"},{"key":"2095_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","volume":"229","author":"M Croft","year":"2009","unstructured":"Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009;229:173\u201391.","journal-title":"Immunol Rev"},{"key":"2095_CR19","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.3390\/jcm10122578","volume":"10","author":"M Furue","year":"2021","unstructured":"Furue M, Furue M. OX40L\u2013OX40 signaling in atopic dermatitis. JCM. 2021;10:2578.","journal-title":"JCM"},{"key":"2095_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00838-9","author":"M Croft","year":"2024","unstructured":"Croft M, Esfandiari E, Chong C, Hsu H, Kabashima K, Kricorian G, et al. OX40 in the pathogenesis of atopic dermatitis\u2014a new therapeutic target. Am J Clin Dermatol. 2024. https:\/\/doi.org\/10.1007\/s40257-023-00838-9.","journal-title":"Am J Clin Dermatol"},{"key":"2095_CR21","doi-asserted-by":"publisher","first-page":"12411","DOI":"10.1038\/s41598-023-39311-2","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ding Y, Wang Q, Pan W, Wei Z, Smith PA, et al. Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4R\u03b1, for the treatment of Th2 inflammatory diseases. Sci Rep. 2023;13:12411.","journal-title":"Sci Rep"},{"key":"2095_CR22","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/cts.13656","volume":"16","author":"J Wang","year":"2023","unstructured":"Wang J, White J, Sansone KJ, Spelman L, Sinclair R, Yang X, et al. Rademikibart (CBP -201), a next-generation monoclonal antibody targeting human IL-4R\u03b1\u202f: two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clin Transl Sci. 2023;16:2614\u201327.","journal-title":"Clin Transl Sci"},{"key":"2095_CR23","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaci.2023.11.924","volume":"153","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Strober B, Feinstein B, Xu J, Guttman-Yassky E, Simpson EL, et al. Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4R\u03b1, in adults with moderate to severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001). J Allergy Clin Immunol. 2024;153:1040\u20139 (e12).","journal-title":"J Allergy Clin Immunol"},{"key":"2095_CR24","unstructured":"Zhang J, Li P, Guo J, Yun J, Yun J, Wei Z, et al. CBP-201, a next-generation IL-4R\u03b1 antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): a randomized, double-blind, pivotal trial in China (CBP-201-CN002). 2023 Annual Meeting of the American Academy of Dermatology (AAD 2023); New Orleans, LA, USA; March 17\u201321, 2023."},{"key":"2095_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/CM9.0000000000002747","volume":"137","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zhang J, Yang B, Li J, Ding Y, Wu L, et al. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2b trial. Chin Med J. 2024;137:130\u20139.","journal-title":"Chin Med J"},{"key":"2095_CR26","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s13555-023-01010-1","volume":"13","author":"CJ Wynne","year":"2023","unstructured":"Wynne CJ, Cole A, Lemech C, Wang G, Zhang Y, Chen B, et al. Safety, pharmacokinetics and preliminary efficacy of IL4-R\u03b1 monoclonal antibody AK120 in both healthy and atopic dermatitis subjects: a phase I, randomized, two-part, double-blind, placebo-controlled, dose-escalation, first-in-human clinical study. Dermatol Ther (Heidelb). 2023;13:2357\u201373.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"2095_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109677","volume":"253","author":"F Cevikbas","year":"2023","unstructured":"Cevikbas F, Ward A, Firth C, Veverka K. Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers. Clin Immunol. 2023;253: 109677.","journal-title":"Clin Immunol"},{"key":"2095_CR28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jaad.2023.10.026","volume":"90","author":"KA Veverka","year":"2024","unstructured":"Veverka KA, Thng STG, Silverberg JI, Armstrong AW, Menezes J, Kaoukhov A, et al. Safety and efficacy of eblasakimab, an interleukin 13 receptor \u03b11 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. J Am Acad Dermatol. 2024;90:504\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"2095_CR29","unstructured":"Simpson E, Gooderham M, Kircik LH, Schlesinger T, Del Rosso J, Murrell D, et al. Topline results from TREK-AD: a randomized, double-blind, placebo-controlled, Phase 2b study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. 2023 European Academy of Dermatology and Venereology Congress (32nd EADV Congress 2023); Berlin, Germany; October 11-14, 2023."},{"key":"2095_CR30","unstructured":"ASLAN Pharmaceuticals. ASLAN pharmaceuticals to present additional data from interim analysis of TREK-DX phase 2 study of Eblasakimab in Dupilumab-experienced atopic dermatitis patients during virtual KOL event. 2024. https:\/\/ir.aslanpharma.com\/news-releases\/news-release-details\/aslan-pharmaceuticals-present-additional-data-interim-analysis. Accessed May 31, 2024."},{"key":"2095_CR31","unstructured":"Tha\u00e7i D, Laquer V, Lynde C, Reich A, Soong W, Worm M, et al. Efficacy and safety of IL-22RA1 inhibition in patients with moderate-to-severe atopic dermatitis: results from a Phase 2a monotherapy trial. 2023 European Academy of Dermatology and Venereology Congress (32nd EADV Congress 2023); Berlin, Germany; October 11-14, 2023"},{"key":"2095_CR32","doi-asserted-by":"crossref","unstructured":"Gooderham M, Reich A, Laquer V, Lynde C, Soong W, Worm M, et al. Individual patient responses to IL-22RA1 inhibition in a Phase 2a monotherapy trial for moderate-to-severe atopic dermatitis. 82nd Annual Meeting of the American Academy of Dermatology (AAD); San Diego, California, USA; March 08-12, 2024.","DOI":"10.1016\/j.jaad.2024.07.951"},{"key":"2095_CR33","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Nemolizumab: first approval. Drugs. 2022;82:1143\u201350.","journal-title":"Drugs"},{"key":"2095_CR34","unstructured":"Galderma. Galderma receives U.S. FDA approval for Nemluvio\u00ae (nemolizumab) for adult patients living with prurigo nodularis Galderma. https:\/\/www.galderma.com\/news\/galderma-receives-us-fda-approval-nemluvior-nemolizumab-adult-patients-living-prurigo. Accessed August 18, 2024."},{"key":"2095_CR35","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","volume":"376","author":"T Ruzicka","year":"2017","unstructured":"Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti\u2013interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med. 2017;376:826\u201335.","journal-title":"N Engl J Med"},{"key":"2095_CR36","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","volume":"142","author":"K Kabashima","year":"2018","unstructured":"Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142:1121\u201330 (e7).","journal-title":"J Allergy Clin Immunol"},{"key":"2095_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","volume":"145","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz J-D, Wollenberg A, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145:173\u201382.","journal-title":"J Allergy Clin Immunol"},{"key":"2095_CR38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s13555-021-00678-7","volume":"12","author":"R Sidbury","year":"2022","unstructured":"Sidbury R, Alpizar S, Laquer V, Dhawan S, Abramovits W, Loprete L, et al. Pharmacokinetics, safety, efficacy, and biomarker profiles during nemolizumab treatment of atopic dermatitis in adolescents. Dermatol Ther (Heidelb). 2022;12:631\u201342.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"2095_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1917006","volume":"383","author":"K Kabashima","year":"2020","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383:141\u201350.","journal-title":"N Engl J Med"},{"key":"2095_CR40","doi-asserted-by":"crossref","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M, for the Nemolizumab JP01 andJP02 Study Group. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate\u2010to\u2010severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long\u2010term studies*. Br J Dermatol. 2022;186:642\u201351.","DOI":"10.1111\/bjd.20873"},{"key":"2095_CR41","doi-asserted-by":"crossref","unstructured":"Igarashi A, Katsunuma T, Matsumura T, Komazaki H, for the Nemolizumab-JP04 Study Group, Takahashi H, et al. Efficacy and safety of nemolizumab in paediatric patients aged 6\u201312 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. British Journal of Dermatology. 2023;190:20\u20138.","DOI":"10.1093\/bjd\/ljad268"},{"key":"2095_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","volume":"404","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Reich A, Tha\u00e7i D, Legat FJ, Papp KA, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. The Lancet. 2024;404:445\u201360.","journal-title":"The Lancet"},{"key":"2095_CR43","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","volume":"144","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144:482\u201393 (e7).","journal-title":"J Allergy Clin Immunol"},{"key":"2095_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.06.005","volume":"99","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Iizuka H, Nemoto O, Shimabe M, Furukawa Y, Kikuta N, et al. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. J Dermatol Sci. 2020;99:82\u20139.","journal-title":"J Dermatol Sci"},{"key":"2095_CR45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/bjd\/ljad240","volume":"189","author":"S Weidinger","year":"2023","unstructured":"Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol. 2023;189:531\u20139.","journal-title":"Br J Dermatol"},{"key":"2095_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3085","volume":"9","author":"V Tkachev","year":"2017","unstructured":"Tkachev V, Furlan SN, Watkins B, Hunt DJ, Zheng HB, Panoskaltsis-Mortari A, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017;9: eaan3085.","journal-title":"Sci Transl Med."},{"key":"2095_CR47","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/cpt.2539","volume":"111","author":"M Saghari","year":"2022","unstructured":"Saghari M, Gal P, Gilbert S, Yateman M, Porter-Brown B, Brennan N, et al. OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005. Clin Pharma Therapeutics. 2022;111:1121\u201332.","journal-title":"Clin Pharma Therapeutics."},{"key":"2095_CR48","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1093\/bjd\/ljad498.028","volume":"190","author":"S Weidinger","year":"2024","unstructured":"Weidinger S, Blauvelt A, Papp K, Reich A, Lee C-H, Worm M, et al. 523 - Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD). Br J Dermatol. 2024;190:ii24\u20136.","journal-title":"Br J Dermatol"},{"key":"2095_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T, et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. The Lancet. 2023;401:204\u201314.","journal-title":"The Lancet"},{"key":"2095_CR50","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.jid.2018.03.1107","volume":"138","author":"G Gudi","year":"2018","unstructured":"Gudi G, A VC, Gn S, Von Gunten C, Back J, Fang H, et al. Clinical pharmacokinetics and immunogenicity of GBR 830, a first-in-class humanized monoclonal antibody inhibiting OX40 to treat atopic dermatitis. J Investig Dermatol. 2018;138:S185.","journal-title":"J Investig Dermatol"},{"key":"2095_CR51","volume":"3","author":"B Rewerska","year":"2024","unstructured":"Rewerska B, Sher LD, Alpizar S, Pauser S, Pulka G, Mozaffarian N, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2024;3: 100195.","journal-title":"J Allergy Clin Immunol"},{"key":"2095_CR52","unstructured":"Ichnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio With Astria Therapeutics. https:\/\/iginnovate.com\/2024\/01\/16\/ichnos-sciences-enters-licensing-agreement-for-ox40-antagonist-monoclonal-antibody-portfolio-with-astria-therapeutics\/. Accessed May 23, 2024."},{"key":"2095_CR53","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"key":"2095_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100258","volume":"4","author":"J Tietz","year":"2024","unstructured":"Tietz J, Gunde T, Warmuth S, Weinert C, Brock M, Simonin A, et al. A bispecific, tetravalent antibody targeting inflammatory and pruritogenic pathways in atopic dermatitis. JID Innov. 2024;4: 100258.","journal-title":"JID Innov"},{"key":"2095_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/abt\/tbad032","volume":"7","author":"F Deng","year":"2024","unstructured":"Deng F, Qiu Y, Zhang X, Guo N, Hu J, Yang W, et al. GB12-09, a bispecific antibody targeting IL4R\u03b1 and IL31R\u03b1 for atopic dermatitis therapy. Antibody Therapeutics. 2024;7:77\u201387.","journal-title":"Antibody Therapeutics."},{"key":"2095_CR56","doi-asserted-by":"crossref","unstructured":"Luo J, Zhu Z, Zhai Y, Zeng J, Li L, Wang D, et al. The role of TSLP in atopic dermatitis: from pathogenetic molecule to therapeutical target. Tsuji F, editor. Mediators of Inflammation. 2023;2023:1\u20138.","DOI":"10.1155\/2023\/7697699"},{"key":"2095_CR57","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","volume":"80","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, Parnes JR, She D, Crouch S, Rees W, Mo M, et al. Tezepelumab, an anti\u2013thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80:1013\u201321.","journal-title":"J Am Acad Dermatol"},{"key":"2095_CR58","doi-asserted-by":"crossref","unstructured":"Parish JL, Appel JE, Silverberg JI, Zhang C, Teng S-W, Zhang J, et al. Clinical efficacy, safety, and pharmacokinetic profile of bosakitug (BSI-045B), an anti-Thymic Stromal Lymphopoietin (TSLP) mAb in a phase 2 study of moderate and severe atopic dermatitis subjects. Revolutionizing Atopic Dermatitis conference 2024; Chicago, Illinois, USA; June 8-10, 2024.","DOI":"10.1093\/bjd\/ljae266.090"},{"key":"2095_CR59","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","volume":"8","author":"A Maudinet","year":"2019","unstructured":"Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran THC. Ocular surface diseases induced by dupilumab in severe atopic dermatitis. Ophthalmol Ther. 2019;8:485\u201390.","journal-title":"Ophthalmol Ther"},{"key":"2095_CR60","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156:411.","journal-title":"JAMA Dermatol"},{"key":"2095_CR61","first-page":"1","volume":"9","author":"S Ferreira","year":"2020","unstructured":"Ferreira S, Torres T. Conjunctivitis in patients with atopic dermatitis treated with dupilumab. DIC. 2020;9:1\u20138.","journal-title":"DIC"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02095-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02095-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02095-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T08:19:02Z","timestamp":1732781942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02095-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2095"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02095-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"9 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by FCT|FCCN (b-on). No funding has been received for the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jos\u00e9 Miguel Alvarenga has no conflicts of interest. Thomas Bieber was speaker and\/or consultant and\/or investigator for AbbVie, Affibody, Almirall, AnaptysBio, Arena, Asana Biosciences, ASLAN pharma, Bayer Health, BioVerSys, Boehringer Ingelheim, Bristol-Myers Squibb, Connect Pharma, Dermavant, DIECE Therapeutics, Domain Therapeutics, EQRx, Galderma, Glenmark, GSK, Incyte, Innovaderm, IQVIA, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L\u2019Or\u00e9al, MSD, Novartis, Numab, OM-Pharma, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi\/Regeneron, and UCB. He is founder and chairman of the board of the non-profit biotech \u201cDavos Biosciences.\u201d Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"JMA, TB, and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent to Participate\/Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}